AĠĠORNAMENT Ematoloġija / Onkoloġija 2024
Kungress ESMO 2023
Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer that is taxane-naive. Amivantamab combinations therapies are emerging as new options for EGFR mutated advanced NSCLC. Antibody-drug combinations improve outcomes for patients who have metastatic or inoperable breast cancer. Digital health technologies are revolutionising cancer care.
Qed tuża verżjoni eqdem tal-web browser tiegħek, għalhekk xi karatteristiċi jistgħu ma jintwerewx sew.
Rekwiżiti MINIMI: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15-18, Apple Safari 7, SeaMonkey 2.15-2.23.
Meeting Resources19 Oct 2023OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.Access to resources.
OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.
Daily ReporterDatopotamab deruxtecan reached the PFS endpoint for previously treated NSCLC23 Oct 2023TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
Daily Reporter177Lu PSMA-617 itejjeb l-rPFS għal pazjenti b'kanċer tal-prostata reżistenti għall-kastrazzjoni metastatiku li huma taxane-naive23 Oct 2023Is-sejbiet tal-prova PSMAfore huma limitati mill-fatt li ma jurux benefiċċju f'termini ta 'OS.
Irreġistra għall-biljetti jew kabini
Mappa tal-post u Lukandi Madwar
Munich - Holiday Inn Munich - Ċentru tal-Belt, il-Bavarja, il-Ġermanja Munich - Holiday Inn Munich - Ċentru tal-Belt, il-Bavarja, il-Ġermanja
Abbona